Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904–10. https://doi.org/10.1126/science.2530631.
Article CAS PubMed Google Scholar
• Nissen SE, Wolski K, Cho L, et al. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart. 2022;9:e002060. https://doi.org/10.1136/openhrt-2022-002060. Large multicentre study describing differences in Lp(a) levels across different populations with atherosclerotic cardiovascular disease.
Article PubMed PubMed Central Google Scholar
Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis. 2022;355:76–82. https://doi.org/10.1016/j.atherosclerosis.2022.06.1023.
Article CAS PubMed Google Scholar
Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28. https://doi.org/10.1056/NEJMoa0902604.
Article CAS PubMed Google Scholar
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–9. https://doi.org/10.1001/jama.2009.801.
Article CAS PubMed Google Scholar
Collaboration ERF. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–23. https://doi.org/10.1001/jama.2009.1063.
Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12. https://doi.org/10.1056/NEJMoa1109034.
Article CAS PubMed PubMed Central Google Scholar
Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470–7. https://doi.org/10.1016/j.jacc.2013.09.038.
Article CAS PubMed Google Scholar
Kamstrup PR, Nordestgaard BG. Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. JACC Heart Fail. 2016;4:78–87. https://doi.org/10.1016/j.jchf.2015.08.006.
Langsted A, Kamstrup PR, Nordestgaard BG. High Lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: A Mendelian randomization study. Clin Chem. 2017;63:1714–23. https://doi.org/10.1373/clinchem.2017.276931.
Article CAS PubMed Google Scholar
Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40:2760–70. https://doi.org/10.1093/eurheartj/ehy902.
Article CAS PubMed Google Scholar
Wang ZW, Li M, Li JJ, Liu NF. Association of lipoprotein(a) with all-cause and cause-specific mortality: A prospective cohort study. Eur J Intern Med. 2022;106:63–70. https://doi.org/10.1016/j.ejim.2022.09.010.
Article CAS PubMed Google Scholar
Levin MG, Zuber V, Walker VM, et al. Prioritizing the role of major lipoproteins and subfractions as risk factors for peripheral artery disease. Circulation. 2021;144:353–64. https://doi.org/10.1161/CIRCULATIONAHA.121.053797.
Article CAS PubMed PubMed Central Google Scholar
Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol. 2012;32:1732–41. https://doi.org/10.1161/ATVBAHA.112.248765.
Article CAS PubMed Google Scholar
Di Maio S, Lamina C, Coassin S, et al. Lipoprotein(a) and SARS-CoV-2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events. J Intern Med. 2022;291:101–7. https://doi.org/10.1111/joim.13338.
Article CAS PubMed Google Scholar
Jackson CL, Garg PK, Guan W, et al. Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: the multi-ethnic study of atherosclerosis. J Clin Lipidol. 2023. https://doi.org/10.1016/j.jacl.2023.06.002.
Kaiser Y, Daghem M, Tzolos E, et al. Association of Lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022;79:223–33. https://doi.org/10.1016/j.jacc.2021.10.044.
Article CAS PubMed PubMed Central Google Scholar
Chandra S, Nagar S, Shukla A, et al. Correlation of lipoprotein (a) levels and plaque morphology in very young acute coronary syndrome patients using optical coherence tomography. Indian Heart J. 2022;74:357–62. https://doi.org/10.1016/j.ihj.2022.09.001.
Article PubMed PubMed Central Google Scholar
van der Valk FM, Bekkering S, Kroon J, et al. Oxidized Phospholipids on Lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611–24. https://doi.org/10.1161/CIRCULATIONAHA.116.020838.
Article CAS PubMed PubMed Central Google Scholar
Tsimikas S, Duff GW, Berger PB, et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol. 2014;63:1724–34. https://doi.org/10.1016/j.jacc.2013.12.030.
Article CAS PubMed PubMed Central Google Scholar
Naka KK, Bechlioullis A, Marini A, et al. Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: the Ioannina Study. J Clin Lipidol. 2018;12:338–47. https://doi.org/10.1016/j.jacl.2017.12.004.
Puri R, Nissen SE, Arsenault BJ, et al. Effect of C-Reactive protein on Lipoprotein(a)-Associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial. JAMA Cardiol. 2020;5:1136–43. https://doi.org/10.1001/jamacardio.2020.2413.
Wang Y, Wang Z, Yang Q, et al. Autosomal recessive transmission of MYBPC3 mutation results in malignant phenotype of hypertrophic cardiomyopathy. PLoS ONE. 2013;8:e67087. https://doi.org/10.1371/journal.pone.0067087.
Article CAS PubMed PubMed Central Google Scholar
Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur Heart J. 2023;44:1449–60. https://doi.org/10.1093/eurheartj/ehad055.
O’Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014;63:520–7. https://doi.org/10.1016/j.jacc.2013.09.042.
Article CAS PubMed Google Scholar
Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39:2589–96. https://doi.org/10.1093/eurheartj/ehy334.
Article CAS PubMed Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–92. https://doi.org/10.1161/CIRCULATIONAHA.118.037184. Post-hoc analyses of the FOURIER trial showing that in secondary prevention Lp(a) associates with cardiovascular risk, and that degree of Lp(a) reduction when receiving evolocumab is associated with the degree of risk reduction.
Article CAS PubMed Google Scholar
• Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol. 2020;40:255–66. https://doi.org/10.1161/ATVBAHA.119.312951. Large cohort study estimating the needed Lp(a) lowering effect to achieve a 20% cardiovascular risk reduction in secondary prevention as well as showing that the relative cardiovascular risk associated of Lp(a) is similar for individuals with LDL cholesterol below 1.8 mmol/L and above 2.6 mmol/L.
Article CAS PubMed Google Scholar
• Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021;42:1147–56. https://doi.org/10.1093/eurheartj/ehaa1085. Large cohort study finding no increased risk of cancer, infections, respiratory, or endocrine diseases associated with low Lp(a) compared to high Lp(a).
Article CAS PubMed Google Scholar
Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252–60. https://doi.org/10.1373/clinchem.2010.146779.
Article CAS PubMed PubMed Central Google Scholar
Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013;1:220–7. https://doi.org/10.1016/S2213-8587(13)70064-0.
Article CAS PubMed Google Scholar
Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74:2982–94. https://doi.org/10.1016/j.jacc.2019.10.019.
留言 (0)